Rutherford, NJ, July 25, 2023 — – Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, announced today the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent…
Rutherford, NJ, April 13, 2023 — GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, today announced the pricing of a firm commitment underwritten public offering of shares of its common stock with gross proceeds to the Company expected to be approximately $10…
Rutherford, NJ, April 12, 2023 — GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, today announced that it intends to offer shares of common stock in a firm commitment underwritten public offering. The Company intends to use the net proceeds from this…
Rutherford, NJ, March 14, 2023 — GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a shareholder update letter. To Our Valued Shareholders, At the outset, we would like…
INDUSTRY VETERAN TO LEAD NEW CONTINUOUS GLUCOSE MONITORING R&D PROGRAM Rutherford, NJ, Oct. 14, 2022 — GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, announced today that Mark Tapsak, PhD, has joined the Company as Vice President of Sensor Technology, effective immediately….
Rutherford, NJ and Or Yehuda, Israel, June 22, 2022 — GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today that it has provided an update on the development of GlucoTrack 2.0 (or “Gen 2”). In…
To begin trading under the Nasdaq Symbol GCTK Rutherford, NJ and Or Yehuda, Israel, March 14, 2022 — GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), formerly known as Integrity Applications, Inc., (Nasdaq: IGAP), innovator of GlucoTrack®, a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and…